Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Total Liabilities (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Total Liabilities for 13 consecutive years, with $188.8 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 5.73% to $188.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $188.8 million through Dec 2025, up 5.73% year-over-year, with the annual reading at $188.8 million for FY2025, 5.73% up from the prior year.
  • Total Liabilities for Q4 2025 was $188.8 million at Theravance Biopharma, up from $182.8 million in the prior quarter.
  • The five-year high for Total Liabilities was $748.3 million in Q1 2021, with the low at $165.6 million in Q4 2022.
  • Average Total Liabilities over 5 years is $344.5 million, with a median of $180.7 million recorded in 2024.
  • The sharpest move saw Total Liabilities crashed 76.79% in 2022, then increased 19.51% in 2025.
  • Over 5 years, Total Liabilities stood at $713.4 million in 2021, then plummeted by 76.79% to $165.6 million in 2022, then rose by 2.06% to $169.0 million in 2023, then grew by 5.69% to $178.6 million in 2024, then rose by 5.73% to $188.8 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $188.8 million, $182.8 million, and $201.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.